Buy SPRO by Oct 11, 2026.

I was expecting SPRO stock to increase after Tebipenem Hbr(Utebzi) approval from FDA. It seemed to be a no-brainer on paper, GSK handles the marketing after approval and pays milestones and royalties to SPRO. I understand that SPRO quit their other two antibiotic programs, but this one can help people avoid hospital stays to clear up infections previously only treated by IV. Merck intends to begin distribution late in 2026. I think it has been a little disappointing to see …